HOME >> MEDICINE >> NEWS
New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate

Initial results from the OpenMind study, the largest behavioural study to look at both patients' and physicians' perceptions of HIV care in treatment-experienced patients, were revealed today at EACS. The study's findings are anticipated to help physicians implement improved care to HIV patients and help pave the way for better acceptance and integration of other new innovative drugs such as monoclonal antibodies that are increasingly being developed for the management of HIV and other diseases.

The study was conceived to look at attitudes to FUZEON (enfuvirtide), the first approved HIV fusion inhibitor, and an important option for treatment-experienced patients who face HIV resistance. FUZEON presents unique challenges because it is the first self-injectable antiretroviral whereas all other treatments are oral.

Highlights from today's data show that:

  • Patients are more willing to consider and use self-injectable therapy than many physicians anticipate
  • Three-quarters (76%) of patients would consider using a self-injectable HIV therapy if their physician recommended it
  • Worryingly, only one quarter (28%) of patients who are potentially eligible for FUZEON had actually discussed this injectable option with their physicians
  • Only 10% of eligible patients were currently prescribed FUZEON, despite the fact that it is recommended in key international HIV treatment guidelines

This study also identifies some of the main reasons why many physicians may be reluctant to prescribe a treatment of proven efficacy and safety. The reasons include; the physicians' perception that patients would be reluctant to use a self-injectable therapy, the physicians' opinion that the patient would not be able to incorporate FUZEON into their lifestyle and the potential misconception that FUZEON is not appropriately recommended in guidelines.

"Physicians' best intentions in trying to match treatments t
'"/>

Contact: Kate Pogson
kate.pogson@ketchum.com
44-207-611-3552
Ketchum
18-Nov-2005


Page: 1 2

Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics

Post Your Comments:
(Date:7/29/2014)... Premier Women’s Health , a six-physician ... has affiliated with Allegheny Health Network’s renowned Women’s Health ... babies and perform surgical procedures at Heritage Valley Sewickley. ... referred to Allegheny Health Network’s West Penn Hospital ... West Penn Hospital and its highly regarded Women’s Health ...
(Date:7/29/2014)... Boca Raton, FL (PRWEB) July 29, 2014 ... will officially launch its products in the UK in September. ... company’s products will be available Sept. 7 on Amazon.co.uk. , ... has been growing and we are truly looking forward to ... Amazon.co.uk will include OZ Naturals bestselling Vitamin C serum ...
(Date:7/29/2014)... 29, 2014 Representatives with BNatrl announced ... called BNatrl Silver Solution 12ppm . , “It’s ... spokesperson for BNatrl LLC. “It helps boost your immune ... harmful pathogens and microbes.” , BNatrl develops and manufactures ... products, with 10 percent of profits being used to ...
(Date:7/29/2014)... IsoComforter, Inc ., one of the ... the introduction of the innovative new Iso-Hip Wrap. ... for post operative hip replacement patients. The plush design ... benefits of cold therapy while resting, sitting, or standing. ... are done every year. Cold therapy is the ...
(Date:7/29/2014)... July 29, 2014 Regents Health Resources, ... services, has brought health care industry veteran Daryl Demonbreun ... to help lead the company’s ambitious plans to grow ... Health has been moving along at a steady pace ... it up a notch,” says Bob Maier, founder and ...
Breaking Medicine News(10 mins):Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:OZ Naturals to Launch Its Products in the UK 2Health News:BNatrl Launches New Silver Solution Product 2Health News:New IsoComforter Cold Therapy Unit Plus Hip Wrap Gives Post Operative Hip Replacement Patients Faster Recovery Times 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2
(Date:7/29/2014)... , July 29, 2014 ... Market Research "Orthopedic Trauma Fixation Devices Market - Global ... - 2020", the global orthopedic trauma fixation devices market ... is expected to grow at a CAGR of 7.2% ... of USD 9.3 billion in 2020. Browse ...
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... July 29, 2014  Instrumentation Laboratory (IL) today announced the ... corporate logo. This is part of a comprehensive rebranding effort ... in Boston, MA , in 1959, IL ... since 1992.  Other companies in the group include Inova Diagnostics ... ( Barcelona, Spain ).  Like IL, these three ...
Breaking Medicine Technology:Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
Cached News: